- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07911137
Effect of Oxybutynin on Opioid Use After Urologic Surgery in Children
A Randomized Double-Blind Placebo-Controlled Trial Evaluating the Opioid-Sparing Effect of Preoperative Oxybutynin in Children Undergoing Urologic Reconstruction
The goal of this clinical trial is to determine whether giving oxybutynin before urologic reconstruction surgery reduces the amount of opioid pain medication needed in children. Oxybutynin is a medication that helps reduce bladder spasms, which can cause pain and discomfort after surgery.
The main question this study aims to answer is:
Does giving oxybutynin before surgery reduce the amount of opioid pain medication children need during the first 6 hours after surgery?
Researchers will compare oxybutynin with a placebo (a tablet containing no active medication) to see whether oxybutynin reduces opioid use after surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Background
Children undergoing pediatric urologic reconstruction, such as pyeloplasty and hypospadias repair, frequently require urinary drainage via ureteral stent and/or urethral catheter. These tools cause the bladder to contract involuntarily, mediated by muscarinic receptors (i.e., bladder spasms). This leads to increased catheter-related bladder discomfort (CRBD), bladder spasm-associated pain and postoperative opioid use.
Oxybutynin, an antimuscarinic agent, reduces the occurrence of bladder spasms and thus the number and severity of CRBD events and bladder spasm-related pain. This reduction in discomfort/pain may contribute to decreased postoperative opioid use, as suggested by retrospective pediatric data.
Postoperative management of urologic reconstruction surgeries includes PRN administration of opioids and oxybutynin to treat bladder spasm-related discomfort/pain according to institutional practice and prior pediatric urology literature. Oxybutynin takes 1 hour to reach its maximal plasma concentration, during which time significant bladder spasm-related symptoms may already be present when the child is awake. However, opioids such as morphine achieve their maximal effects within 10 minutes. Because opioids are much faster-acting than oxybutynin, this may increase the likelihood of concomitant administration when the child is awake with discomfort/pain. We are therefore considering using oxybutynin preoperatively, rather than just postoperatively PRN, since its plasma concentration will already be maximal or near-maximal upon waking, which may lead to less CRBD, bladder spasm-related pain, and postoperative opioid use.
This study aims to reduce the use of opioids to treat pediatric patients undergoing urologic reconstruction. Opioids carry significant side effects that include nausea, vomiting, respiratory depression, addiction, urinary retention, tolerance, and constipation. Combined with the ongoing opioid epidemic, there is an increased effort among caregivers, including nurses and physicians, to find other means to reduce pain in pediatric patients.
Opioid therapy has also been shown not to be effective in treating bladder spasm-related symptoms (e.g., CRBD, bladder spasm-related pain). As opposed to opioids, oxybutynin directly targets bladder spasm-associated symptoms, and may reduce the severity of side effects. Side effects of oxybutynin include dry mouth, constipation, dizziness, urinary retention, and blurry vision.
Emerging pediatric urology data suggest that a single preoperative dose may reduce early postoperative opioid requirements. However, current evidence is retrospective and non-randomized. There is no high-quality randomized pediatric study evaluating the opioid sparing effects of preoperative oxybutynin administration in pediatric patients undergoing urologic reconstruction.
Study Need, Importance, and Hypothesis
Urologic reconstruction surgeries requiring a stent and/or catheter can be associated with significant CRBD, bladder-spasm associated pain and morbidity. With the growing recognition of the need to decrease opioid medication, our primary objective is to assess whether the administration of preoperative oxybutynin reduces opioid use. We hypothesize that preoperative oxybutynin reduces early postoperative opioid use in children undergoing pyeloplasty or hypospadias repair.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Hayder Al-Kazzaz
- Número de teléfono: 403-955-7757
- Correo electrónico: hayder.alkazzaz@ucalgary.ca
Copia de seguridad de contactos de estudio
- Nombre: Bryce Weber, MD
- Número de teléfono: 403-955-2776
- Correo electrónico: bryce.weber@albertahealthservices.ca
Ubicaciones de estudio
-
-
Alberta
-
Calgary, Alberta, Canadá, T2B6A8
- Alberta Children's Hospital
-
Investigador principal:
- Bryce Weber
-
Contacto:
- Hayder Al-Kazzaz
- Número de teléfono: 403-955-7757
- Correo electrónico: hayder.alkazzaz@ucalgary.ca
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- All children aged 0 to 17 years old admitted for pyeloplasty or hypospadias repair. There is no minimum weight for inclusion
Exclusion Criteria:
- Contraindications to anticholinergic medications
- Urinary retention disorders
- Gastrointestinal obstruction/ileus
- Contraindications to anesthetic protocol, including 1) allergy to any anesthetic medication in protocol, 2) refusal of regional technique, 3) contraindications to ketorolac (i.e., recent GI bleed, recent intracranial bleed, renal dysfunction, acute kidney injury)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Preoperative Oxybutynin
Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
|
Comparador de placebos: Preoperative Placebo
Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total Cumulative Postoperative Opioid Consumption (MME/kg)
Periodo de tiempo: From the end of surgery through 6 hours postoperatively
|
Total cumulative morphine milligram equivalents per kilogram (MME/kg) administered within 6 hours after surgery |
From the end of surgery through 6 hours postoperatively
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of Participants Receiving Postoperative Opioids
Periodo de tiempo: From the end of surgery through 6 hours postoperatively
|
Whether any opioid medication was administered within 6 hours after surgery (yes/no) |
From the end of surgery through 6 hours postoperatively
|
|
Postoperative Pain Scores (NRS/FLACC)
Periodo de tiempo: At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube
|
Pain assessed using age-appropriate validated scales: the Numeric Rating Scale (NRS; 0-10) or the Face, Legs, Activity, Cry, Consolability (FLACC; 0-10) scale. Higher scores indicate greater pain. |
At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube
|
|
Proportion of Participants Receiving Postoperative Rescue Oxybutynin
Periodo de tiempo: From the end of surgery through 6 hours postoperatively
|
Whether oxybutynin was administered as needed (PRN) within 6 hours after surgery (yes/no). |
From the end of surgery through 6 hours postoperatively
|
|
Total Cumulative Postoperative Oxybutynin Consumption (mg/kg)
Periodo de tiempo: From the end of surgery through 6 hours postoperatively
|
Total cumulative dose of oxybutynin administered per kilogram of body weight during the first 6 hours after surgery. |
From the end of surgery through 6 hours postoperatively
|
|
Incidence of Adverse Events
Periodo de tiempo: From preoperative study medication administration through postoperative discharge
|
Occurrence of adverse events, including dry mouth, flushing, tachycardia, agitation, sedation, and urinary retention. |
From preoperative study medication administration through postoperative discharge
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Dolor
- Manifestaciones neurológicas
- Complicaciones Postoperatorias
- Procesos Patológicos
- Enfermedades Genitales Masculinas
- Enfermedades urogenitales masculinas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Anomalías congénitas
- Anomalías urogenitales
- Enfermedades del pene
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor Postoperatorio
- Hipospadias
- Displasia renal multicítica, bilateral
- oxibutinín
Otros números de identificación del estudio
- REB26-1464
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .